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Abstract
Background: Smoking is the most important individual risk factor for many cancer sites but its association with
breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of
smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure
(smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung,
breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.
Methods: This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data
for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of
smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important
potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given
smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.
Results: Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up
of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years,
respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung
cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk
of cancer development and mortality compared with continued smoking.
Conclusions: This investigation shows that smoking, even among older adults, considerably advances, and cessation
delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating
the harmful effects of smoking and the beneficial effect of smoking cessation.
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Background
Although the global age-standardized smoking prevalence
has decreased over the last 30 years, absolute numbers of
smokers have increased with nearly one billion daily
smokers worldwide in 2012 [1]. Today, smoking is a well-
established risk factor for many common cancers [2–10].
However, associations with breast and prostate cancer
are still a matter of debate [11–13]. The findings for
these outcomes are often summarized with meta-analyses
of published aggregate data. These are often subject to
limitations regarding the estimations and conversions per-
formed on the published data, the lack of or the variability
of confounder adjustment between studies, the hetero-
geneity in the methodology employed, the variability of
available data, and the populations included. Conducting
meta-analyses of individual participant data would over-
come such methodological shortcomings [14].
Standard epidemiological risk estimates, such as risk
ratios, may not always be easily understood by the general
population [15, 16] and might fail to properly communicate
the harmful impact of smoking on cancer development and
mortality. Rate advancement periods (RAPs) are de-
signed to enhance quantification and communication
of the harmful effect of smoking and the beneficial ef-
fect of quitting [17–19]. Thus, if the age at which a
given level of cancer risk is reached is 65 years for
never smokers and 55 years for current smokers, the
RAP for current smoking would be 10 years, as the time
would be advanced (or shortened) by this amount. Fur-
thermore, if the age for that given level of risk is 59 years
for those who have quit smoking for a defined time (e.g.,
10-19 years) the RAP for quitting, expressed relative to
current smoking, would be -4 years, as the time would
be delayed by 4 years. Moreover, for cancers with avail-
able effective screening measures, RAPs may also pro-
vide useful information for a possible adaptation of the
age at initiation of screening.
Therefore, we sought to quantify for the first time with
RAPs the association of smoking exposure with total
and site-specific cancer incidence and mortality using
data from 19 population-based cohorts participating in
the Consortium on Health and Aging: Network of Cohorts
in Europe and the United States (CHANCES).
Methods
Study population
CHANCES is a coordinated multi-country study which
aims at facilitating the harmonization of data from on-
going prospective cohort studies in Europe and the USA
in order to produce evidence on aging-related health
characteristics and on determinants of healthy aging among
the elderly in these countries (www.chancesfp7.eu) [20].
From all available participating studies in CHANCES, a
total of 897,021 participants from 19 cohorts with cancer
incidence/mortality data and smoking characteristics were
included. Additional file 1: Table S1 provides an overview
of the most important cohort characteristics. More detailed
descriptions of included cohorts are openly available on the
internet [21]. All included CHANCES cohorts obtained in-
formed consent from all participants and were conducted
according to the declaration of Helsinki.
Definition of endpoints
Vital status and information on the cause of death was
obtained from regional or state registries for all cohorts.
Cancer incidence was ascertained by active follow-up or
record linkage with national/regional cancer registries
for most cohorts, except the HAPIEE cohorts and the
SENECA study in which follow-up for cancer incidence
was not performed. The main endpoints were total cancer
incidence and mortality, as defined by codes C00-C97
according to the 10th edition of the International Classifi-
cation of Diseases (ICD-10). Additional endpoints were in-
cidence and mortality of the most frequent cancers in the
CHANCES data that are known to be related to smoking,
i.e., head and neck (C00-16, C30-32), gastric (C16), colon
and rectum (C18 -20), pancreatic (C25), and lung cancer
(C34), as well as cancers for which an association with
smoking has not yet been established, i.e., breast (C50)
and prostate cancer (C61).
Smoking exposure assessment
Smoking status, categorized as never (reference), former,
and current smoker was the main exposure and was
available for all studies. Time since smoking cessation
(≤9, 10 to 19, and ≥ 20 years ago) was available for all
studies except for the Rotterdam study. Additionally, in-
formation on time since smoking cessation could not be
harmonized for NIH-AARP and MORGAM FI studies.
Current smokers were set as reference for the analyses
of cancer risk with respect to time since smoking cessation.
Smoking intensity (≤9, 10 to 19, or ≥ 20 smoked cigarettes
per day) was available for all cohorts except SENECA. Dur-
ation of smoking (≤19, 20 to 39, or ≥ 40 years) was available
for all cohorts but NIH-AARP.
Statistical analyses
For analyses with cancer mortality outcomes, we included
all participants with complete information on smoking
status and vital status [n = 856,039 (95 %)]. For the ana-
lyses with cancer incidence outcomes, we only included
participants without a prevalent cancer [n = 803,910
(90 %)]. Participants with missing values for the covariates
included in the multivariable model [n = 76,441 (9 %)]
were excluded from the analysis. Other approaches to deal
with missing values, such as multiple imputation, may lead
to bias [22] and do not increase precision substantially
when missing data are less than 10 % [23].
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Cox proportional hazard models were used to estimate
hazard ratios (HR) and 95 % confidence intervals (CI)
for the association of smoking exposure with cancer out-
comes. We created two different models: one adjusted
for age and sex only; and a multivariable model that
included the most important common potential con-
founder variables for all endpoints that were also common
to all included cohorts, i.e., age (continuous, years), sex,
education (primary or less, more than primary but less
than university or college, and university or college), vigor-
ous physical activity (yes, no), history of diabetes (yes, no),
BMI (continuous, kg/m2), and daily alcohol intake
(continuous, g/day). In MORGAM Finland and Sweden
cohorts physical activity was not available and therefore
not adjusted for.
RAPs for a given smoking exposure variable (“smok_
expo”) were calculated from the HRs for that given
smoking exposure variable and the HR for age obtained
in the Cox models by applying the following formula:
RAPsmok_expo = (log HRsmok_expo)/(log HRage). The cal-
culation of their 95 % confidence intervals has been de-
scribed in more detail elsewhere [24]. This calculation
of the RAPs assumes that the risk of the disease expo-
nentially increases with age, which is a fair assumption
for cancer and is commonly made in Cox regression
models including age as a linear term.
For both HRs and RAPs, sex- and age-stratified (youn-
ger or older than 65 years) analyses were conducted.
Risk estimates for each cohort were derived from the in-
dividual participant data using a common analysis-script
that runs in SAS, version 9.3 (Cary, NC, USA).
In order to allow for the variability of the true effect
size between cohorts, meta-analyses with random effects
models were used to derive summary HRs and RAPs
[25]. Heterogeneity was tested for significance using
Cochran’s Q test and quantified by the I2 estimate [26].
It was regarded as negligible if not significant (P < 0.05)
or I2 < 30 %. Otherwise, if significant (P < 0.05), it was
classified as moderate (30 % < I2 < 50 %), substantial
(50 % < I2 < 75 %), or considerable (I2 > 75 %). When the
heterogeneity was considerable, stratification of the
meta-analyses according to cohort characteristics was
carried out in order to examine possible sources of het-
erogeneity. Meta-analyses and tests of heterogeneity
were derived in Microsoft Excel 2010 (Redmond, WA,
USA) using the formulas described by Borenstein et al.
[27]. Dose-response relations were assessed by meta-
analysis for dose-response data using the Greenland and
Longnecker method [28] and a random effects model as
described elsewhere [29]. All statistical tests were two-
sided using an alpha level of 0.05. This report was pre-
pared in accordance with the PRISMA guidelines for the
reporting of meta-analyses with individual participant
data studies [30].
Results
Socio-demographic and lifestyle characteristics of the
participants at baseline across cohorts are shown in
Table 1. The average age of participants was 60 years
(ranging from 46 to 74 years). The proportion of men
was similar in most cohorts, except for cohorts of men
(COSM and MORGAM NI) or women (EPIC-Elderly
NL and SMC). Despite variation across cohorts, the ma-
jority of participants were overweight, had an education
under the university level (except NIH-AARP), and low
consumption of alcohol. In total, 346,559 (39 %) partici-
pants were never smokers, 368,808 (41 %) former smokers,
and 140,672 (16 %) current smokers.
Association of smoking exposure with total and
respiratory tract cancer incidence and mortality
The differences in risk estimates between the model ad-
justed only for age and sex and the multivariable model
were lower than 10 % (data not shown); thus, only the
results for the multivariable model are reported in detail.
Smoking status was associated with increasing total,
lung, and head and neck cancer incidence and mortality
(Table 2). RAPs for current smokers ranged from 7.9 to
30.0 years and were stronger for cancer mortality than
incidence outcomes, with the exception of lung cancer.
Longer time since smoking cessation was associated with
decreasing cancer incidence and mortality, with largest
risk reductions for lung cancer followed by head and
neck cancer and lastly total cancer. Higher smoking
intensity and duration were associated with larger ad-
vancements in total, lung, and head and neck cancer
risk and mortality (Additional file 2: Table S2).
Overall, considerable heterogeneity between studies
was observed (I2 > 75 %), particularly for total and lung
cancer outcomes. Risk estimates were largest in the
United States, followed by Eastern Europe, and then by
other regions of Europe (Additional files 3 and 4: Tables
S3 and S4 for total and lung cancer, respectively). Larger
effects were seen with shorter follow-ups, more recent
initiation of the study, and among studies with lower
numbers of cases.
Association of smoking exposure with digestive tract
cancer incidence and mortality
Smoking status was also associated with higher colorectal,
gastric, and pancreatic cancer incidence and mortality
(Table 3). RAPs for colorectal, gastric, and pancreatic
cancer incidence were similar to those for mortality.
Being a current smoker (compared with never smoking)
significantly advanced the risk of developing colorectal,
gastric, and pancreatic cancer by 3.6, 5.6, and 7.6 years,
respectively. Quitting smoking (compared with not
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Table 1 Socio-demographic and lifestyle characteristics at baseline of the participants included for cohorts in the CHANCES consortium
COSM EPIC-Elderly ESTHER HAPIEE MORGAM NIH-
AARP
RS SENECA SMC TROMSØ VIP
DK ES GR NL CZ LT PO RU FI NI SE
N total 45,906 15,355 5185 9863 6896 9949 8857 7161 10,728 9360 38,108 2745 5476 566,279 8121 2585 38,984 10,463 95,000
Follow-up (years)a 13 13 13 10 13 11 8 4 7 6 17 16 11 12 12 8 13 13 14
Age (years)a 59 63 62 67 64 63 59 62 57 58 46 54 53 63 69 74 61 62 50
Sex, %
Male 100 46 43 40 5 45 47 45 49 46 48 100 49 60 39 50 0 47 50
Female 0 54 57 60 95 55 53 55 51 54 52 0 51 40 61 50 100 53 50
BMI (kg/m2)a 25 26 29 29 26 27 28 29 28 28 26 26 27 26 26 27 24 26 25
Education, %
Primary 70 41 87 91 34 75 13 7 12 10 46 1 31 1 25 67 74 56 23
Secondary 14 43 7 6 55 20 74 37 60 61 44 88 49 26 62 25 7 28 51
University 16 16 6 3 11 5 14 56 29 29 9 11 20 73 8 8 18 16 26
Alcohol (g/day)a 10 12 1 1 2 4 6 0 0 0 2 9 2 2 3 3 3 2 3
Vigorous physical activity, %
Yes 34 72 5 21 58 42 73 61 73 40 n.a. 12 n.a. 46 85 13 30 32 34
No 66 28 95 79 42 58 27 39 27 60 88 54 15 87 70 68 66
History of diabetes, %
Yes 7 3 11 14 5 16 12 8 12 5 5 2 5 9 7 9 5 4 2
No 93 97 89 86 95 84 88 92 88 95 95 98 95 91 93 91 95 96 98
Smoking status, %
Never 36 31 67 70 47 50 44 63 40 58 46 38 48 36 36 54 54 33 55
Former 39 36 16 19 35 33 30 18 28 14 29 33 32 51 41 28 23 36 25
Current 25 33 17 12 18 17 26 19 32 28 25 29 20 12 23 18 23 31 20
Time since smoking cessation, %
≤9 years 22 28 41 36 26 23 30 34 41 38 n.a. 36 38 26 n.a. 39 28 31 37
10–19 years 29 22 30 31 29 28 29 23 29 26 35 26 74 30 28 24 32
≥20 years 49 41 27 30 43 48 36 43 24 33 29 34 28 44 45 24
aThe values shown are the mean for follow-up years and the median for age, BMI, and alcohol consumption
Abbreviations (alphabetically ordered): BMI body mass index, COSM Cohort of Swedish Men, CZ Czech Republic, DK Denmark, EPIC European Prospective Investigation into Cancer and Nutrition, ES Spain, ESTHER
Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung (German), GR Greece. HAPIEE Health, Alcohol and Psychosocial
factors In Eastern Europe, LT Lithuania, MORGAM Monica Risk, Genetics, Archiving and Monograph, which included the cohorts MORGAM FI FINRISK Study (Finland), MORGAM NI PRIME Belfast Study (Northern Ireland),
and MORGAM SE Northern Sweden Study (Norrbotten county only), NIH-AARP National Institute of Health – American Association of Retired Persons, NL the Netherlands, PO Poland, RS Rotterdam Study, RU Russia,
SENECA Survey in Europe on Nutrition and the Elderly a Concerned Action, SMC Swedish Mammography Cohort, VIP Västerbotten Intervention Programme
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Table 2 Associations of smoking status and time since smoking cessation with total, lung, head and neck cancer incidence and mortalitya,b
Cancer site Smoking
exposure
Cancer incidence Cancer mortality
Totalc Cases HR (95 % CI) RAP (95 % CI) Totalc Cases HR (95 % CI) RAP (95 % CI)
Total cancer Smoking status
Never 321984 43449 1.00 (reference) 0.00 (reference) 346559 13398 1.00 (reference) 0.00 (reference)
Former 353311 64797 1.15 (1.09 ; 1.21)*** 2.67 (1.65 ; 3.70)** 368808 24365 1.39 (1.26 ; 1.54)*** 4.03 (2.85 ; 5.22)***
Current 128615 26007 1.44 (1.28 ; 1.63)*** 7.92 (5.58 ; 10.3)*** 140672 13450 2.19 (1.83 ; 2.63)*** 9.92 (7.84 ; 12.0)***
Years since smoking cessation (reference: current smokers)d
≤9 years 19049 2704 0.90 (0.86 ; 0.94) -1.62 (-2.41; -0.83) 22693 1351 0.83 (0.77 ; 0.89) -2.09 (-2.86 ; -1.31)
10–19 years 18511 2613 0.80 (0.74 ; 0.88)** -4.01 (-5.73; -2.29)** 21361 1145 0.66 (0.59 ; 0.73) -4.81 (-6.01 ; -3.62)
≥20 years 24651 3904 0.75 (0.70 ; 0.81)** -5.27 (-6.69; -3.86)* 28057 1507 0.52 (0.47 ; 0.58)* -7.54 (-8.59 ; -6.49)
P linear trend <0.0001 <0.0001
Lung cancer Smoking status
Never 321984 923 1.00 (reference) 0.00 (reference) 346559 863 1.00 (reference) 0.00 (reference)
Former 353311 6785 4.06 (3.13 ; 5.26)** 16.4 (12.2 ; 20.7)*** 368808 6967 4.10 (3.14 ; 5.36)*** 15.3 (11.7; 18.9)**
Current 128615 6333 13.1 (9.90 ; 17.3)*** 30.0 (24.1 ; 35.9)*** 140672 6165 11.5 (8.21 ; 16.1)*** 26.2 (21.5; 30.8)***
Years since smoking cessation (reference: current smokers)d
≤9 years 19049 306 0.60 (0.48 ; 0.73)* -5.26 (-7.91; -2.61)* 22693 373 0.70 (0.56 ; 0.87)** -3.45 (-5.33 ; -1.56)
10–19 years 18511 191 0.33 (0.25 ; 0.44)** -12.3 (-16.4; -8.20)** 21361 233 0.40 (0.31 ; 0.51)* -8.99 (-12.2 ; -5.77)**
≥20 years 24651 139 0.15 (0.12 ; 0.19) -21.9 (-28.1; -15.8)** 28057 168 0.18 (0.14 ; 0.24)* -17.0 (-21.3 ; -12.7)**
P linear trend <0.0001 <0.0001
Head and neck cancer Smoking status
Never 321984 636 1.00 (reference) 0.00 (reference) 346559 155 1.00 (reference) 0.00 (reference)
Former 353311 1503 1.73 (1.57 ; 1.92) 7.77 (4.24 ; 11.3) 368808 388 2.10 (1.70 ; 2.61) 9.01 (4.36 ; 13.6)
Current 128615 1051 2.89 (1.98 ; 4.21)** 9.10 (-2.34 ; 20.5)*** 140672 359 3.74 (2.38 ; 5.89) 14.0 (4.53 ; 23.5)**
Years since smoking cessation (reference: current smokers)d
≤9 years 19049 64 1.08 (0.80 ; 1.47) -0.77 (-3.97 ; 3.66) 22693 22 1.35 (0.75 ; 2.44) -2.64 (-4.11 ; 9.40)
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Table 2 Associations of smoking status and time since smoking cessation with total, lung, head and neck cancer incidence and mortalitya,b (Continued)
10–19 years 18511 33 0.61 (0.40 ; 0.92) -5.71 (-15.4 ; 1.19) 21361 14 1.35 (0.62 ; 2.90) 3.45 (-7.93 ; 14.8)
≥20 years 24651 53 0.55 (0.34 ; 0.91) -2.75 (-9.26 ; 3.76) 28057 20 0.58 (0.31 ; 1.07) -3.59 (-10.1 ; 2.91)
P linear trend 0.0039 0.0676
aNumbers in bold denote statistical significance (P < 0.05). Heterogeneity was regarded as negligible if not significant (P < 0.05) or I2 < 30 %. Otherwise, if significant (P < 0.05), it was classified as * moderate (30 %
< I2 < 50 %), ** substantial (50 % < I2 < 75 %), or *** considerable (I2 > 75 %)
bCohort-specific Hazard Ratios (HRs) and Rate Advancement Periods (RAPs) were summarized with meta-analyses using random effects models. HRs and RAPs were adjusted for sex, age, BMI, education, vigorous
physical activity, history of diabetes, and alcohol consumption
cThe total number of participants for the analyses with cancer incidence is smaller because the participants with a diagnosis of cancer before baseline were excluded. Furthermore, some cohorts (HAPIEE and SENECA
cohorts) had no cancer incidence data available for the analyses
dFor the analyses with the categories of years since smoking cessation, the data from the NIH-AARP and MORGAM FI were not included because of the different categories employed
HAPIEE Health, Alcohol and Psychosocial Factors in Eastern Europe, SENECA Survey in Europe on Nutrition and the Elderly a Concerned Action, NIH-AARP National Institute of Health – American Association of Retired
Persons, MORGAM Monica Risk, Genetics, Archiving and Monograph, which included the cohort MORGAM FI FINRISK Study (Finland)
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quitting) significantly delayed the risk of development
of, and death from, colorectal (up to 3.2 years), gastric
(up to 5.6 years), and pancreatic cancer (up to
10.4 years). Higher smoking intensity and duration
were in most cases associated with larger advance-
ments in digestive tract cancer risk and mortality
(Additional file 5: Table S5). The degree of heterogeneity
between studies in the meta-analyses was mostly negligible
(P > 0.05 and I2 < 30 %).
Association of smoking exposure with sex-specific cancer
incidence and mortality
Smoking status was significantly associated with moder-
ate increases in breast cancer incidence and mortality,
although RAPs suggested larger advancements in the
risk of both outcomes (Table 4). Smoking intensity was
furthermore tentatively associated with breast cancer in-
cidence and more strongly associated with breast cancer
mortality (Additional file 6: Table S6).
Table 3 Associations of smoking status and time since smoking cessation with colorectal, gastric and pancreatic cancer incidence
and mortalitya,b
Cancer site Smoking
exposure
Cancer incidence Cancer mortality
Totalc Cases HR (95 % CI) RAP (95 % CI) Totalc Cases HR (95 % CI) RAP (95 % CI)
Colorectal cancer Smoking status
Never 321984 4359 1.00 (reference) 0.00 (reference) 346559 1702 1.00 (reference) 0.00 (reference)
Former 353311 6273 1.20 (1.15 ; 1.25) 2.62 (2.00 ; 3.24) 368808 2264 1.22 (1.13 ; 1.31) 2.19 (1.35 ; 3.02)
Current 128615 2064 1.20 (1.07 ; 1.34)* 3.64 (2.81 ; 4.46) 140672 912 1.35 (1.16 ; 1.58) 4.61 (3.53 ; 5.68)
Years since smoking cessation (reference: current smokers)d
≤9 years 19049 318 1.00 (0.87 ; 1.16) -0.11 (-1.94 ; 1.72) 22693 152 1.07 (0.86 ; 1.32) 0.22 (-2.09 ; 2.53)
10–19 years 18511 365 1.11 (0.97 ; 1.27) 1.16 (-0.53 ; 2.84) 21361 167 1.07 (0.87 ; 1.31) 0.31 (-1.83 ; 2.45)
≥20 years 24651 514 0.88 (0.78 ; 1.00) -1.95 (-3.58 ; -0.32) 28057 205 0.76 (0.63 ; 0.93) -3.18 (-5.24 ; -1.11)
P linear trend 0.1885 0.0134
Gastric cancer Smoking status
Never 321984 598 1.00 (reference) 0.00 (reference) 346559 463 1.00 (reference) 0.00 (reference)
Former 353311 880 1.18 (0.95; 1.46) 1.80 (-0.31 ; 3.91) 368808 631 1.31 (1.02 ; 1.68) 2.08 (0.02 ; 4.14)
Current 128615 388 1.74 (1.50; 2.02) 5.62 (3.85 ; 7.39) 140672 302 1.73 (1.36 ; 2.19) 5.22 (3.08 ; 7.36)
Years since smoking cessation (reference: current smokers)d
≤9 years 19049 54 0.85 (0.60 ; 1.20) -3.02 (-6.43 ; 0.40) 22693 61 1.13 (0.80 ; 1.58) -0.59 (-3.90 ; 2.72)
10–19 years 18511 51 0.68 (0.41 ; 1.12) -3.48 (-7.00 ; 0.05) 21361 45 0.72 (0.46 ; 1.14) -2.62 (-6.57 ; 1.32)
≥20 years 24651 77 0.69 (0.51 ; 0.93) -2.42 (-5.08 ; 0.24) 28057 77 0.87 (0.64 ; 1.19) -1.89 (-5.25 ; 1.47)
P linear trend 0.0461 0.2355
Pancreatic
cancer
Smoking status
Never 321984 921 1.00 (reference) 0.00 (reference) 346559 1186 1.00 (reference) 0.00 (reference)
Former 353311 1216 1.13 (0.95 ; 1.35) 1.45 (0.23 ; 2.67) 368808 1609 1.19 (0.98 ; 1.45) 1.85 (0.85 ; 2.86)
Current 128615 635 1.90 (1.48 ; 2.43)* 7.57 (4.31 ; 10.8)* 140672 808 2.19 (1.74 ; 2.75)** 8.50 (6.45 ; 10.5)
Years since smoking cessation (reference: current smokers)d
≤9 years 19049 74 0.83 (0.62 ; 1.11) -2.16 (-6.01 ; 1.69) 22693 93 0.72 (0.56 ; 0.93) -3.78 (-6.73 ; -0.84)
10–19 years 18511 62 0.71 (0.52 ; 0.96) -4.82 (-9.11 ; -0.53) 21361 81 0.63 (0.48 ; 0.82) -5.57 (-8.74 ; -2.40)
≥20 years 24651 65 0.47 (0.31 ; 0.70) -9.72 (-15.3 ; -4.15) 28057 104 0.48 (0.35 ; 0.67) -10.4 (-13.7 ; -7.16)
P linear trend <0.0001 <0.0001
aNumbers in bold denote statistical significance (P < 0.05). Heterogeneity was regarded as negligible if not significant (P < 0.05) or I2 < 30 %. Otherwise, if
significant (P < 0.05), it was classified as * moderate (30 % < I2 < 50 %), ** substantial (50 % < I2 < 75 %), or *** considerable (I2 > 75 %)
bCohort-specific Hazard Ratios (HRs) and Rate Advancement Periods (RAPs) were summarized with meta-analyses using random effects models. HRs and RAPs
were adjusted for sex, age, BMI, education, vigorous physical activity, history of diabetes and alcohol consumption
cThe total number of participants for the analyses with cancer incidence is smaller because the participants with a diagnosis of cancer before baseline were
excluded. Furthermore, some cohorts (HAPIEE and SENECA cohorts) had no cancer incidence data available for the analyses
dFor the analyses with the categories of years since smoking cessation, the data from the NIH-AARP and MORGAM FI were not included because they had different
categories available
HAPIEE Health, Alcohol and Psychosocial Factors in Eastern Europe, SENECA Survey in Europe on Nutrition and the Elderly a Concerned Action, NIH-AARP National
Institute of Health – American Association of Retired Persons, MORGAM Monica Risk, Genetics, Archiving and Monograph, which included the cohort MORGAM FI
FINRISK Study (Finland)
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Smoking status was associated with lower prostate
cancer incidence, but associated with higher prostate
cancer mortality (although not reaching statistical sig-
nificance). RAPs for current smokers suggested a 2.9 year
delay in prostate cancer risk compared with never
smokers; but an advancement of 1.9 years in the risk of
dying from prostate cancer. Overall, time since smoking
cessation was not significantly associated with prostate
cancer outcomes, but a 1.7 year delay in the risk of dying
from prostate cancer was observed among those who
stopped smoking more than 20 years previously, com-
pared with those who were still smokers at the initiation
of the study. Smoking intensity was also inversely associ-
ated with prostate cancer incidence but associated with
increased mortality (Additional file 6: Table S6).
Sex- and age-stratified analyses of smoking exposure and
cancer incidence and mortality
Overall, smoking status was associated with cancer in-
cidence and mortality for all sites with few differences
between men and women (Fig. 1). Only for lung and gastric
cancer incidence, stronger risks were observed among
former or current smoking men when compared with
women. In both men and women, longer time since
smoking cessation was associated with significant de-
creases in total, lung, and pancreatic cancer incidence and
mortality (Fig. 2). RAPs were homogeneous among sexes.
Overall, the associations of smoking status and time
since smoking cessation with cancer outcomes were similar
for younger and older adults (under and above 65 years, re-
spectively). Only for lung cancer incidence and mortality, a
clearly larger relative increase in cancer risk among current
smokers (Fig. 3), and a larger relative reduction in cancer
risk with longer time since smoking cessation (Fig. 4) was
observed among younger compared with older adults. The
results with RAPs were homogeneous among age groups.
Discussion
In this large individual participant meta-analysis of 19
cohort studies including data from 897,021 adults from
Table 4 Associations of smoking status and time since smoking cessation with sex-specific cancer incidence and mortalitya,b
Cancer site Smoking
exposure
Cancer incidence Cancer mortality
Totalc Cases HR (95 % CI) RAP (95 % CI) Totalc Cases HR (95 % CI) RAP (95 % CI)
Breast cancer Smoking status
Never 174507 7121 1.00 (reference) 0.00 (reference) 191907 1197 1.00 (reference) 0.00 (reference)
Former 116656 5428 1.08 (1.04 ; 1.12) 2.37 (0.68 ; 4.06) 121725 905 1.15 (1.05 ; 1.27) 2.71 (0.78 ; 4.63)
Current 59755 2536 1.07 (1.00 ; 1.15) 3.83 (1.76 ; 5.91) 64470 466 1.28 (1.06 ; 1.55) 5.10 (2.47 ; 7.72)
Years since smoking cessation (reference: current smokers)d
≤9 years 8348 275 0.97 (0.84 ; 1.13) -2.49 (-7.49 ; 2.52) 9726 49 0.98 (0.57 ; 1.67) -1.82 (-8.21; 4.57)
10–19 years 7044 253 1.03 (0.81 ; 1.31) -3.87 (-9.84 ; 2.10) 8092 43 1.02 (0.70 ; 1.49) 0.51 (-7.55 ; 8.57)
≥20 years 8437 333 1.03 (0.85 ; 1.24) -3.77 (-10.2 ; 2.66) 9539 61 1.23 (0.69 ; 2.21) -0.56 (-8.57 ; 1.48)
P linear trend 0.7293 0.4549
Prostate
cancer
Smoking status
Never 147477 11090 1.00 (reference) 0.00 (reference) 154652 920 1.00 (reference) 0.00 (reference)
Former 236655 17257 0.88 (0.82 ; 0.95)* -1.67 (-2.80; -0.54)** 247083 1644 1.04 (0.94 ; 1.15) 0.29 (-0.33 ; 0.91)
Current 68860 3701 0.81 (0.72 ; 0.91)** -2.89 (-4.81; -0.97)** 76202 589 1.26 (0.97 ; 1.64)** 1.88 (0.25 ; 3.51)
Years since smoking cessation (reference: current smokers)d
≤9 years 10701 536 1.00 (0.90 ; 1.12) 0.51 (-0.83 ; 1.84) 12967 98 0.94 (0.64 ; 1.37) -1.03 (-3.35 ; 1.30)
10–19 years 11467 702 1.03 (0.89 ; 1.19) 1.09 (-0.17 ; 2.35) 13269 130 0.95 (0.74 ; 1.20) -0.43 (-2.18 ; 1.32)
≥20 years 16214 1227 1.08 (0.99 ; 1.18) 0.75 (-0.38 ; 1.88) 18518 228 0.82 (0.67 ; 1.00) -1.71 (-3.18; -0.24)
P linear trend 0.0480 0.0838
aNumbers in bold denote statistical significance (P < 0.05). Heterogeneity was regarded as negligible if not significant (P < 0.05) or I2 < 30 %. Otherwise, if
significant (P < 0.05), it was classified as * moderate (30 % < I2 < 50 %), ** substantial (50 % < I2 < 75 %), or *** considerable (I2 > 75 %)
bCohort-specific Hazard Ratios (HRs) and Rate Advancement Periods (RAPs) were summarized with meta-analyses using random effects models. HRs and RAPs
were adjusted for sex, age, BMI, education, vigorous physical activity, history of diabetes, and alcohol consumption
cThe total number of participants equals to the total number of women (for breast cancer) or men (for prostate cancer). The total number of participants for
the analyses with cancer incidence is smaller because the participants with a diagnosis of cancer before baseline were excluded. Furthermore, some cohorts
(HAPIEE and SENECA cohorts) had no cancer incidence data available for the analyses
dFor the analyses with the categories of years since smoking cessation, the data from the NIH-AARP and MORGAM FI were not included because they had different
categories available
HAPIEE Health, Alcohol and Psychosocial Factors in Eastern Europe, SENECA Survey in Europe on Nutrition and the Elderly a Concerned Action, NIH-AARP National
Institute of Health – American Association of Retired Persons, MORGAM Monica Risk, Genetics, Archiving and Monograph, which included the cohort MORGAM FI
FINRISK Study (Finland)
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Europe and the United States, we observed that current
smoking advanced the risk of developing and dying from
any cancer by almost 8 and 10 years, respectively, com-
pared with never smokers. The benefit of quitting was
observed both immediately and in the long run with as
much as 2 years delay in the risk of developing and
dying from cancer in those who quit only less than
10 years ago. This benefit increased to almost 8 years
delay in the risk of cancer death among those who quit
more than 20 years ago.
Overall, relative risk estimates for smoking were larger
for cancer mortality than for cancer incidence. There
may be two main explanations for this finding: first,
smoking is more strongly associated with cancers that
have a poor prognosis, such as lung cancer. Second,
smoking also adversely affects prognosis after cancer
diagnosis as underlined in the 2014 Report of the Sur-
geon General [2]. The association of smoking exposure
with the different cancer sites greatly varied in magnitude,
with HRs and RAPs being largest for lung, followed by
head and neck, pancreatic, gastric, colorectal, and breast
cancer, in this declining order. Inconsistent associations of
smoking exposure with prostate cancer incidence and
mortality were observed.
Large heterogeneity between studies was observed for
total and lung cancer, the main contributor being the
study location, with larger effect sizes observed in North
America than in Europe. Such geographical difference
has previously been described for lung cancer [4]. Other
cohort characteristics, such as the year of initiation of
the study and the length of follow-up, may have also
contributed to the heterogeneity although to a lesser
degree. In particular, stratification of our analyses by sex
or age did not reduce the heterogeneity. For all other
cancer sites, heterogeneity was largely negligible.
The magnitudes of the effects observed were compar-
able to those previously seen in the literature, especially
for lung [4], head and neck [7], gastric [8], and pancreatic
cancer [9, 10]. For colorectal, breast, and prostate cancer
there has been more debate as to whether smoking is a
true risk factor. We will therefore discuss these cancer
sites in the following paragraphs.
Previous studies on colorectal cancer have mostly
focused on the impact of smoking on incidence [5].
We provide substantial evidence that cigarette smoking
increases colorectal cancer mortality. In previous meta-
analyses, larger increases in risk among former smokers
than current smokers were often observed suggesting a
Fig. 1 Sex-stratified association of smoking status with cancer incidence and mortality. Hazard ratios (HR) and 95 % confidence intervals (CI) for
cancer incidence and mortality are depicted on the vertical axis for current and former smokers (never smokers as reference). Cohort-specific HRs
and 95 % CIs were pooled with meta-analyses separately for men (black squares) and women (white squares)
Ordóñez-Mena et al. BMC Medicine  (2016) 14:62 Page 9 of 15
long lasting effect of smoking [5, 6]. Although in our study
current smokers had increased colorectal cancer incidence
and mortality, risk reductions were not visible for time
since smoking cessation shorter than 20 years, which rein-
forces the before-mentioned suggestions. We also ob-
served increased colorectal cancer incidence and mortality
with greater smoking intensity and duration, which further
suggests a causal role of smoking in colorectal cancer de-
velopment. Furthermore, little to no variation by sex and
age was observed, therefore suggesting that the impact of
cigarette smoking and time since smoking cessation on
colorectal cancer is independent of sex and age.
Previous studies have reported weak associations of to-
bacco smoking with breast cancer incidence which is in
line with our findings [11, 31–33]. There has been de-
bate as to the extent to which the effect of smoking on
breast cancer incidence might be due to confounding by
alcohol consumption [31–33]. While some have observed
increased breast cancer risks associated with smoking
among nondrinkers [31], and others among drinkers [32],
a more recent analysis concluded that risk did not differ
by alcohol consumption [33]. In our analyses we observed
statistically significant advancements in the risk of breast
cancer incidence and mortality among current and former
smokers compared with never smokers, even after
adjusting for alcohol consumption. However, no con-
sistent associations with time since cessation, smoking
intensity, and duration were observed.
Our finding that current smokers had lower prostate
cancer incidence than never smokers is consistent with
reports from previous studies [13, 34]. However, this
apparent protective effect seems to be confined only to
low-grade/localized prostate tumors, whereas higher-
grade/advanced prostate tumors were directly associated
with smoking [13]. We observed higher prostate cancer
mortality among current smokers and an advancement
of nearly 2 years of the risk of prostate cancer death
among current smokers. We also observed a delay in the
risk of prostate cancer mortality by nearly 2 years after
20 years since smoking cessation. Furthermore, both
higher smoking intensity and duration were associated
with increased prostate cancer mortality. A plausible ex-
planation for the apparent differences between prostate
cancer incidence and mortality may be that current
smokers might be less likely to seek medical attention and
undergo prostate cancer screening than never smokers,
therefore being less often diagnosed with low-grade/local-
ized tumors. Alternatively, mechanisms have been proposed
Fig. 2 Sex-stratified association of time since smoking cessation with cancer incidence and mortality. Hazard ratios (HR) and 95 % confidence
intervals (CI) for cancer incidence and mortality are depicted on the vertical axis for smoking cessation≤ 9 years ago, 10–19 years ago, or≥ 20 years
ago (current smokers as reference). Cohort-specific HRs and 95 % CIs were pooled with meta-analyses separately for men (black squares) and women
(white squares)
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by which cigarette smoking could protect against prostate
cancer [13, 34].
Our main advantage was the availability of harmonized
individual participant data for the estimation of cohort-
specific risk estimates. This allowed us to define and use
similar categories of exposure, similar disease endpoints,
and common multivariable models among the included
studies. Our investigation also included only prospective
cohort studies, which reduces the potential of biases,
often of concern in retrospective studies, such as recall
and selection bias. Finally, due to the large sample size
of our analyses we were able to assess the association of
smoking exposure with cancer endpoints among older
adults (>65 years) and thereby to provide specific evi-
dence that the detrimental effects of smoking and the
benefits of cessation prevail even at old age.
Our main limitation refers to the assessment of smok-
ing status, which relies on the validity of the participants’
responses in the questionnaires. Since we only employed
baseline data, some of the current smokers at baseline
may have quit during follow-up, thus cancer risk among
current smokers may have been underestimated. On the
other hand, some quitters may have resumed smoking
which could have led to an overestimation of cancer risk
among former smokers. Although we adjusted for the
most important common confounders, due to the lack
of relevant covariates in some of the included cohorts,
the possibility of residual confounding cannot be ex-
cluded. Dietary variables or family history of cancer have
been related to smoking status [35–37]. However, due to
their weak effects on cancer risk, their influence in the
association of smoking with cancer is expected to be
Fig. 3 Age-stratified association of smoking status with cancer incidence and mortality. Hazard ratios (HR) and 95 % confidence intervals (CI) for
cancer incidence and mortality are depicted on the vertical axis for current and former smokers (never smokers as reference). Cohort-specific HRs
and 95 % CIs were pooled with meta-analyses separately for older than 65 years old (black circles) and younger than 65 years old (white circles)
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very small. Finally, despite our large sample size we could
only focus on the most common cancer sites across all
included cohorts.
Conclusions
We showed that smoking increases cancer incidence and
mortality in all sites (except for prostate cancer inci-
dence) and that quitting smoking is still beneficial at old
age. Lastly, although there have been other attempts to
quantify the benefits of smoking cessation in years by
which the excess in cancer risk is decreased [38, 39], we
have shown for the first time with RAPs how smoking
significantly advances the risk of developing and dying
from major cancers, being a better communication tool
than the concept of risk alone. Risk communication is
especially crucial in promoting smoking cessation and
RAPs could be easier to grasp for the general public
considering the benefits of quitting. RAPs are certainly
less susceptible to the sort of bias highlighted by Peto
[40], whereby the fact that relative risks fall after quitting
implies nothing about absolute risks (which grow more
slowly). Given the higher susceptibility of older adults to
the harmful effects of smoking and the lack of smoking-
specific public health policies aimed at this group [41, 42],
the results of this study underline the need for continued
and enhanced efforts to decrease tobacco smoking preva-
lence in Europe and the United States.
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